KR100533476B1 - 핵이식용의 휴지기 세포 모집단 - Google Patents
핵이식용의 휴지기 세포 모집단 Download PDFInfo
- Publication number
- KR100533476B1 KR100533476B1 KR1019980701381A KR19980701381A KR100533476B1 KR 100533476 B1 KR100533476 B1 KR 100533476B1 KR 1019980701381 A KR1019980701381 A KR 1019980701381A KR 19980701381 A KR19980701381 A KR 19980701381A KR 100533476 B1 KR100533476 B1 KR 100533476B1
- Authority
- KR
- South Korea
- Prior art keywords
- cells
- cell
- donor
- animal
- embryos
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000000034 method Methods 0.000 claims abstract description 75
- 210000001161 mammalian embryo Anatomy 0.000 claims abstract description 29
- 210000004027 cell Anatomy 0.000 claims description 156
- 210000000287 oocyte Anatomy 0.000 claims description 40
- 238000012546 transfer Methods 0.000 claims description 38
- 241000283690 Bos taurus Species 0.000 claims description 15
- 241000124008 Mammalia Species 0.000 claims description 10
- 241001494479 Pecora Species 0.000 claims description 6
- 210000001082 somatic cell Anatomy 0.000 claims description 6
- 241000283707 Capra Species 0.000 claims description 5
- 241000699670 Mus sp. Species 0.000 claims description 5
- 241000282887 Suidae Species 0.000 claims description 4
- 241000283086 Equidae Species 0.000 claims description 2
- 241000700159 Rattus Species 0.000 claims description 2
- 241001465754 Metazoa Species 0.000 abstract description 58
- 230000000284 resting effect Effects 0.000 abstract description 16
- 108090000623 proteins and genes Proteins 0.000 abstract description 9
- 230000008901 benefit Effects 0.000 abstract description 8
- 238000010449 nuclear transplantation Methods 0.000 abstract description 7
- 230000007910 cell fusion Effects 0.000 abstract description 4
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 230000035519 G0 Phase Effects 0.000 abstract 1
- 210000002257 embryonic structure Anatomy 0.000 description 40
- 239000002609 medium Substances 0.000 description 32
- 108020003175 receptors Proteins 0.000 description 31
- 102000005962 receptors Human genes 0.000 description 31
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 30
- 239000012894 fetal calf serum Substances 0.000 description 29
- 210000004940 nucleus Anatomy 0.000 description 27
- 230000004913 activation Effects 0.000 description 26
- 210000002459 blastocyst Anatomy 0.000 description 26
- 230000004927 fusion Effects 0.000 description 19
- 238000011161 development Methods 0.000 description 15
- 230000018109 developmental process Effects 0.000 description 15
- 241000894007 species Species 0.000 description 14
- 238000000338 in vitro Methods 0.000 description 12
- 238000001727 in vivo Methods 0.000 description 12
- 239000011575 calcium Substances 0.000 description 11
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 10
- 229910052791 calcium Inorganic materials 0.000 description 10
- 230000022131 cell cycle Effects 0.000 description 10
- 210000003101 oviduct Anatomy 0.000 description 10
- 238000002054 transplantation Methods 0.000 description 10
- 210000000805 cytoplasm Anatomy 0.000 description 9
- 229920001817 Agar Polymers 0.000 description 8
- 210000001015 abdomen Anatomy 0.000 description 8
- 239000008272 agar Substances 0.000 description 8
- 230000006698 induction Effects 0.000 description 8
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 239000002953 phosphate buffered saline Substances 0.000 description 7
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 6
- 229930195725 Mannitol Natural products 0.000 description 6
- 101000882406 Staphylococcus aureus Enterotoxin type C-1 Proteins 0.000 description 6
- 239000012153 distilled water Substances 0.000 description 6
- 210000002950 fibroblast Anatomy 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 239000000594 mannitol Substances 0.000 description 6
- 235000010355 mannitol Nutrition 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 5
- 210000000349 chromosome Anatomy 0.000 description 5
- 210000004748 cultured cell Anatomy 0.000 description 5
- 230000035935 pregnancy Effects 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 210000003370 receptor cell Anatomy 0.000 description 5
- 208000004860 Blast Crisis Diseases 0.000 description 4
- 108010077544 Chromatin Proteins 0.000 description 4
- 230000006820 DNA synthesis Effects 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 230000001488 breeding effect Effects 0.000 description 4
- 210000003483 chromatin Anatomy 0.000 description 4
- 210000002919 epithelial cell Anatomy 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 210000004602 germ cell Anatomy 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 230000001850 reproductive effect Effects 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 210000004340 zona pellucida Anatomy 0.000 description 4
- 241000711408 Murine respirovirus Species 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- GBOGMAARMMDZGR-UHFFFAOYSA-N UNPD149280 Natural products N1C(=O)C23OC(=O)C=CC(O)CCCC(C)CC=CC3C(O)C(=C)C(C)C2C1CC1=CC=CC=C1 GBOGMAARMMDZGR-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000009395 breeding Methods 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- GBOGMAARMMDZGR-JREHFAHYSA-N cytochalasin B Natural products C[C@H]1CCC[C@@H](O)C=CC(=O)O[C@@]23[C@H](C=CC1)[C@H](O)C(=C)[C@@H](C)[C@@H]2[C@H](Cc4ccccc4)NC3=O GBOGMAARMMDZGR-JREHFAHYSA-N 0.000 description 3
- GBOGMAARMMDZGR-TYHYBEHESA-N cytochalasin B Chemical compound C([C@H]1[C@@H]2[C@@H](C([C@@H](O)[C@@H]3/C=C/C[C@H](C)CCC[C@@H](O)/C=C/C(=O)O[C@@]23C(=O)N1)=C)C)C1=CC=CC=C1 GBOGMAARMMDZGR-TYHYBEHESA-N 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 230000003780 keratinization Effects 0.000 description 3
- 210000002510 keratinocyte Anatomy 0.000 description 3
- 230000035800 maturation Effects 0.000 description 3
- 210000004508 polar body Anatomy 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 230000008672 reprogramming Effects 0.000 description 3
- PRDFBSVERLRRMY-UHFFFAOYSA-N 2'-(4-ethoxyphenyl)-5-(4-methylpiperazin-1-yl)-2,5'-bibenzimidazole Chemical compound C1=CC(OCC)=CC=C1C1=NC2=CC=C(C=3NC4=CC(=CC=C4N=3)N3CCN(C)CC3)C=C2N1 PRDFBSVERLRRMY-UHFFFAOYSA-N 0.000 description 2
- NMJREATYWWNIKX-UHFFFAOYSA-N GnRH Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CC(C)C)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 NMJREATYWWNIKX-UHFFFAOYSA-N 0.000 description 2
- KYRVNWMVYQXFEU-UHFFFAOYSA-N Nocodazole Chemical compound C1=C2NC(NC(=O)OC)=NC2=CC=C1C(=O)C1=CC=CS1 KYRVNWMVYQXFEU-UHFFFAOYSA-N 0.000 description 2
- 241000283903 Ovis aries Species 0.000 description 2
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000012888 bovine serum Substances 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 238000002224 dissection Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 2
- 210000003979 eosinophil Anatomy 0.000 description 2
- 210000002165 glioblast Anatomy 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 229930027917 kanamycin Natural products 0.000 description 2
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 2
- 229960000318 kanamycin Drugs 0.000 description 2
- 229930182823 kanamycin A Natural products 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000031864 metaphase Effects 0.000 description 2
- 238000000520 microinjection Methods 0.000 description 2
- 230000011278 mitosis Effects 0.000 description 2
- 230000027291 mitotic cell cycle Effects 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 229950006344 nocodazole Drugs 0.000 description 2
- 230000006911 nucleation Effects 0.000 description 2
- 238000010899 nucleation Methods 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 210000002826 placenta Anatomy 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 210000004989 spleen cell Anatomy 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 235000002198 Annona diversifolia Nutrition 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 108010037003 Buserelin Proteins 0.000 description 1
- 241000282832 Camelidae Species 0.000 description 1
- 241001550206 Colla Species 0.000 description 1
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 1
- 108091029865 Exogenous DNA Proteins 0.000 description 1
- 230000010190 G1 phase Effects 0.000 description 1
- 230000010558 Gene Alterations Effects 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 206010020112 Hirsutism Diseases 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 102000006947 Histones Human genes 0.000 description 1
- 241000282838 Lama Species 0.000 description 1
- 235000019687 Lamb Nutrition 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 108020005196 Mitochondrial DNA Proteins 0.000 description 1
- 102000007399 Nuclear hormone receptor Human genes 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 230000018199 S phase Effects 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 208000034790 Twin pregnancy Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000004026 adhesive bonding Methods 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000001109 blastomere Anatomy 0.000 description 1
- CUWODFFVMXJOKD-UVLQAERKSA-N buserelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 CUWODFFVMXJOKD-UVLQAERKSA-N 0.000 description 1
- 229960002719 buserelin Drugs 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 108091092328 cellular RNA Proteins 0.000 description 1
- 210000003793 centrosome Anatomy 0.000 description 1
- 230000010428 chromatin condensation Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000030944 contact inhibition Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 108091007930 cytoplasmic receptors Proteins 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 230000005059 dormancy Effects 0.000 description 1
- 210000003981 ectoderm Anatomy 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 210000002308 embryonic cell Anatomy 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 201000010063 epididymitis Diseases 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 230000008175 fetal development Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 238000005189 flocculation Methods 0.000 description 1
- 230000016615 flocculation Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 238000003198 gene knock in Methods 0.000 description 1
- 238000003209 gene knockout Methods 0.000 description 1
- 238000010363 gene targeting Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 230000004077 genetic alteration Effects 0.000 description 1
- 231100000118 genetic alteration Toxicity 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 210000002175 goblet cell Anatomy 0.000 description 1
- 210000002149 gonad Anatomy 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000002768 hair cell Anatomy 0.000 description 1
- 244000144980 herd Species 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000016507 interphase Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 235000013622 meat product Nutrition 0.000 description 1
- PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 description 1
- 230000004066 metabolic change Effects 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 210000000472 morula Anatomy 0.000 description 1
- 210000002894 multi-fate stem cell Anatomy 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 230000002352 nonmutagenic effect Effects 0.000 description 1
- 210000000633 nuclear envelope Anatomy 0.000 description 1
- 235000018343 nutrient deficiency Nutrition 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 238000007500 overflow downdraw method Methods 0.000 description 1
- 230000016087 ovulation Effects 0.000 description 1
- RLZZZVKAURTHCP-UHFFFAOYSA-N phenanthrene-3,4-diol Chemical compound C1=CC=C2C3=C(O)C(O)=CC=C3C=CC2=C1 RLZZZVKAURTHCP-UHFFFAOYSA-N 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 210000002729 polyribosome Anatomy 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000003488 releasing hormone Substances 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 210000005132 reproductive cell Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 208000001608 teratocarcinoma Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000003151 transfection method Methods 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 238000000539 two dimensional gel electrophoresis Methods 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/873—Techniques for producing new embryos, e.g. nuclear transfer, manipulation of totipotent cells or production of chimeric embryos
- C12N15/877—Techniques for producing new mammalian cloned embryos
- C12N15/8771—Bovine embryos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/873—Techniques for producing new embryos, e.g. nuclear transfer, manipulation of totipotent cells or production of chimeric embryos
- C12N15/877—Techniques for producing new mammalian cloned embryos
- C12N15/8773—Ovine embryos
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Developmental Biology & Embryology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Reproductive Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Gynecology & Obstetrics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Environmental Sciences (AREA)
- Biodiversity & Conservation Biology (AREA)
- Animal Husbandry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9517780.4 | 1995-08-31 | ||
| GBGB9517780.4A GB9517780D0 (en) | 1995-08-31 | 1995-08-31 | Biological manipulation |
| PCT/GB1996/002099 WO1997007669A1 (en) | 1995-08-31 | 1996-08-30 | Quiescent cell populations for nuclear transfer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020057014692A Division KR100793220B1 (ko) | 1995-08-31 | 1996-08-30 | 핵이식용의 휴지기 세포 모집단 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR19990044148A KR19990044148A (ko) | 1999-06-25 |
| KR100533476B1 true KR100533476B1 (ko) | 2006-04-21 |
Family
ID=10779998
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019980701381A Expired - Lifetime KR100533476B1 (ko) | 1995-08-31 | 1996-08-30 | 핵이식용의 휴지기 세포 모집단 |
| KR1020067006297A Ceased KR20060053008A (ko) | 1995-08-31 | 1996-08-30 | 핵이식용의 휴지기 세포 모집단 |
| KR1020077007530A Withdrawn KR20070047848A (ko) | 1995-08-31 | 1996-08-30 | 핵이식용의 휴지기 세포 모집단 |
| KR1020057014692A Expired - Lifetime KR100793220B1 (ko) | 1995-08-31 | 1996-08-30 | 핵이식용의 휴지기 세포 모집단 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020067006297A Ceased KR20060053008A (ko) | 1995-08-31 | 1996-08-30 | 핵이식용의 휴지기 세포 모집단 |
| KR1020077007530A Withdrawn KR20070047848A (ko) | 1995-08-31 | 1996-08-30 | 핵이식용의 휴지기 세포 모집단 |
| KR1020057014692A Expired - Lifetime KR100793220B1 (ko) | 1995-08-31 | 1996-08-30 | 핵이식용의 휴지기 세포 모집단 |
Country Status (23)
| Country | Link |
|---|---|
| US (5) | US6147276A (enExample) |
| EP (3) | EP0849990B1 (enExample) |
| JP (2) | JP4081613B2 (enExample) |
| KR (4) | KR100533476B1 (enExample) |
| CN (3) | CN1769431A (enExample) |
| AT (1) | ATE199115T1 (enExample) |
| AU (1) | AU716956C (enExample) |
| BR (1) | BR9610034B1 (enExample) |
| CA (1) | CA2229568C (enExample) |
| CZ (1) | CZ60898A3 (enExample) |
| DE (1) | DE69611793T2 (enExample) |
| DK (1) | DK0849990T3 (enExample) |
| ES (1) | ES2155197T3 (enExample) |
| GB (2) | GB9517780D0 (enExample) |
| HU (1) | HUP9900234A3 (enExample) |
| IL (1) | IL123298A0 (enExample) |
| NO (1) | NO980845L (enExample) |
| NZ (3) | NZ316149A (enExample) |
| PL (1) | PL325331A1 (enExample) |
| SG (1) | SG75155A1 (enExample) |
| SI (1) | SI0849990T1 (enExample) |
| WO (1) | WO1997007669A1 (enExample) |
| ZA (1) | ZA967390B (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101398220B1 (ko) | 2006-10-30 | 2014-05-22 | 건국대학교 산학협력단 | 형질전환 배아 생성방법 |
Families Citing this family (227)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5480772A (en) | 1993-02-03 | 1996-01-02 | Brandeis University | In vitro activation of a nucleus |
| GB9517780D0 (en) * | 1995-08-31 | 1995-11-01 | Roslin Inst Edinburgh | Biological manipulation |
| GB9517779D0 (en) * | 1995-08-31 | 1995-11-01 | Roslin Inst Edinburgh | Biological manipulation |
| US7307198B2 (en) | 1995-08-31 | 2007-12-11 | Roslin Institute | Ungulates produced by nuclear transfer of G1 cells |
| US6025155A (en) * | 1996-04-10 | 2000-02-15 | Chromos Molecular Systems, Inc. | Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes |
| US6077697A (en) | 1996-04-10 | 2000-06-20 | Chromos Molecular Systems, Inc. | Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes |
| US7696404B2 (en) | 1996-08-19 | 2010-04-13 | Advanced Cell Technology, Inc. | Embryonic or stem-like cell lines produced by cross species nuclear transplantation and methods for enhancing embryonic development by genetic alteration of donor cells or by tissue culture conditions |
| US6271436B1 (en) | 1996-10-11 | 2001-08-07 | The Texas A & M University System | Cells and methods for the generation of transgenic pigs |
| US20090092588A1 (en) * | 1997-01-10 | 2009-04-09 | University Of Massachusetts As Represented By Its Amherst Campus | Cloned ungulate embryos and animals, use of cells, tissues and organs thereof for transplantation therapies including parkinson's disease |
| US6235969B1 (en) * | 1997-01-10 | 2001-05-22 | University Of Massachusetts | Cloning pigs using donor nuclei from non-quiescent differentiated cells |
| US5945577A (en) * | 1997-01-10 | 1999-08-31 | University Of Massachusetts As Represented By Its Amherst Campus | Cloning using donor nuclei from proliferating somatic cells |
| US6215041B1 (en) * | 1997-01-10 | 2001-04-10 | University Of Mmassachusetts | Cloning using donor nuclei from a non-quiesecent somatic cells |
| GB9703550D0 (en) * | 1997-02-20 | 1997-04-09 | Ppl Therapeutics Scotland Ltd | Cell mediated transgenesis |
| US6011197A (en) | 1997-03-06 | 2000-01-04 | Infigen, Inc. | Method of cloning bovines using reprogrammed non-embryonic bovine cells |
| EP0981604B1 (en) * | 1997-04-24 | 2009-01-07 | University of Washington | Targeted gene modification by parvoviral vectors |
| WO1998057984A2 (en) | 1997-06-19 | 1998-12-23 | The General Hospital Corporation | Torsin, torsin genes, and methods of use |
| US6921814B2 (en) | 1997-06-19 | 2005-07-26 | The General Hospital Corporation | Torsin, torsin-related genes and methods of detecting neuronal disease |
| IL133786A0 (en) * | 1997-07-03 | 2001-04-30 | Univ Massachusetts | Cloning using donor nuclei from non-serum starved, differentiated cells |
| AU8587598A (en) * | 1997-07-26 | 1999-02-16 | Wisconsin Alumni Research Foundation | Trans-species nuclear transfer |
| JP2001513336A (ja) * | 1997-08-22 | 2001-09-04 | ロスリン インスティチュート（エディンバラ） | トランスジェニック動物の生産における「マリーナ」トランスポザンの使用 |
| EP1009818A1 (en) * | 1997-09-02 | 2000-06-21 | Cancer Research Campaign Technology Limited | A cell-free replication system and uses thereof |
| WO1999021415A1 (en) * | 1997-10-28 | 1999-05-06 | Stem Cell Sciences Pty. Ltd. | Nuclear transfer for production of transgenic animal embryo |
| WO1999036510A1 (de) * | 1998-01-16 | 1999-07-22 | Agrobiogen Gmbh | Effizienter kerntransfer mit fetalen fibroblasten |
| US6331659B1 (en) * | 1998-01-21 | 2001-12-18 | University Of Hawaii | Cumulus cells as nuclear donors |
| CA2324009A1 (en) * | 1998-03-16 | 1999-09-23 | Relag Pty Ltd. | Porcine nuclear transfer |
| AUPP294898A0 (en) * | 1998-04-15 | 1998-05-07 | Monash University | Method of nuclear transfer |
| GB9808325D0 (en) * | 1998-04-20 | 1998-06-17 | Ltr Ciz Di Associazione Italia | Source of nuclei for nuclear transfer |
| GB9809178D0 (en) * | 1998-04-29 | 1998-07-01 | Univ Edinburgh | Nuclear reprogramming of somatic cells |
| GB2365445A (en) | 1998-10-12 | 2002-02-20 | Geron Bio Med Ltd | Porcine occcytes with improved developmental competence |
| US6580017B1 (en) | 1998-11-02 | 2003-06-17 | Genzyme Transgenics Corporation | Methods of reconstructed goat embryo transfer |
| AU2003204830B2 (en) * | 1998-11-02 | 2007-08-30 | Gtc Biotherapeutics, Inc. | Transgenic and cloned mammals |
| CA2350233A1 (en) * | 1998-11-02 | 2000-05-11 | Genzyme Transgenics Corp. | Transgenic and cloned mammals |
| EP1375654A3 (en) * | 1998-11-02 | 2008-01-16 | GTC Biotherapeutics, Inc. | Transgenic and cloned mammals |
| US6781030B1 (en) | 1998-11-02 | 2004-08-24 | Trustee Of Tufts College, Ballou Hall | Methods for cloning mammals using telophase oocytes |
| NZ511299A (en) | 1998-11-19 | 2003-02-28 | Ppl Therapeutics Scotland Ltd | Stabilisation of milk from transgenic animals through expression of a serine proteinase inhibitor and optionally fibrinogen in the mammary gland |
| US6258998B1 (en) | 1998-11-24 | 2001-07-10 | Infigen, Inc. | Method of cloning porcine animals |
| US6700037B2 (en) | 1998-11-24 | 2004-03-02 | Infigen, Inc. | Method of cloning porcine animals |
| JP2002534118A (ja) * | 1999-01-13 | 2002-10-15 | ピーピーエル セラピューティクス （スコットランド） リミテッド | 二重核移植法及びその結果物 |
| GB9903805D0 (en) * | 1999-02-20 | 1999-04-14 | Univ Sheffield | Pluripotential cells-1 |
| GB9903804D0 (en) * | 1999-02-20 | 1999-04-14 | Univ Sheffield | Pluripotential cells-2 |
| EP2301947A3 (en) | 1999-02-26 | 2011-11-23 | Millennium Pharmaceuticals, Inc. | Secreted proteins and uses thereof |
| US20020012660A1 (en) * | 1999-03-04 | 2002-01-31 | Alan Colman | Method of preparing a somatic cells for nuclear transfer |
| WO2000051424A2 (en) | 1999-03-04 | 2000-09-08 | Ppl Therapeutics (Scotland) Ltd. | Genetic modification of somatic cells and uses thereof |
| NZ515159A (en) * | 1999-04-28 | 2003-03-28 | Univ Montreal | Telophase enucleated oocytes for nuclear transfer |
| IL146829A0 (en) * | 1999-06-04 | 2002-07-25 | Istituto Zootecnico E Caseario | Process for reconstructing a non-human animal embryo by nuclear transfer and preparing the animal therefrom, and embryos and animal obtained thereby |
| AU5553600A (en) | 1999-06-23 | 2001-01-31 | Ppl Therapeutics (Scotland) Ltd | Fusion proteins incorporating lysozyme |
| CA2334953A1 (en) * | 1999-06-30 | 2001-01-04 | Woo-Suk Hwang | Method for producing human cloned embryos by employing inter-species nuclear transplantation technique |
| US6590139B1 (en) | 1999-06-30 | 2003-07-08 | Woo-Suk Hwang | Method for producing cloned cows |
| BR0012099A (pt) * | 1999-06-30 | 2003-07-29 | Advanced Cell Tech Inc | Transferência citoplásmica para de-diferenciar células recipientes |
| EP1117763A4 (en) * | 1999-06-30 | 2004-12-01 | Hwang Woo Suk | PROCESS FOR PRODUCING CLONED TIGERS USING INTER-SPECIES CORE TRANSPLANTATION TECHNIQUE |
| US7291714B1 (en) | 1999-06-30 | 2007-11-06 | Millennium Pharmaceuticals, Inc. | Glycoprotein VI and uses thereof |
| PT1210428E (pt) | 1999-08-23 | 2015-07-21 | Genetics Inst Llc | Pd-1, um recetor para b7-4 e suas utilizações |
| EP2275559A3 (en) | 1999-09-28 | 2011-03-23 | Shire Human Genetic Therapies, Inc. | Optimized messenger RNA |
| WO2002064799A2 (en) | 1999-09-28 | 2002-08-22 | Transkaryotic Therapies, Inc. | Optimized messenger rna |
| CA2385015A1 (en) * | 1999-09-30 | 2001-04-05 | Genzyme Transgenics Corporation | Methods of producing cloned and transgenic mammals |
| US7414170B2 (en) * | 1999-11-19 | 2008-08-19 | Kirin Beer Kabushiki Kaisha | Transgenic bovines capable of human antibody production |
| US7820878B2 (en) * | 1999-11-19 | 2010-10-26 | Kyowa Hakko Kirin Co., Ltd. | Production of ungulates, preferably bovines that produce human immunoglobulins |
| KR100417566B1 (ko) * | 1999-11-19 | 2004-02-05 | 한국생명공학연구원 | 체세포 핵치환 복제수정란의 대량생산방법 |
| US7074983B2 (en) * | 1999-11-19 | 2006-07-11 | Kirin Beer Kabushiki Kaisha | Transgenic bovine comprising human immunoglobulin loci and producing human immunoglobulin |
| WO2001035735A1 (en) * | 1999-11-19 | 2001-05-25 | Hematech, Llc | Production of ungulates, preferably bovines that produce human immunoglobulins |
| US6635802B1 (en) * | 2000-01-10 | 2003-10-21 | The Texas A&M University System | Nuclear transfer using cells cultured in serum starvation media containing apoptosis inhibitors |
| GB0001401D0 (en) * | 2000-01-22 | 2000-03-08 | Univ Edinburgh | Methods for amplifying genetic material and use thereof |
| CA2403344C (en) | 2000-03-15 | 2013-05-21 | The University Of Georgia Research Foundation, Inc. | Effective nuclear reprogramming in mammals |
| US20040033600A1 (en) | 2001-03-21 | 2004-02-19 | Palli Subba Reddy | Ecdysone receptor-based inducible gene expression system |
| GB2360522A (en) | 2000-03-24 | 2001-09-26 | Geron Corp | A strategy for maintaining pregnancy |
| WO2001088096A2 (en) * | 2000-05-15 | 2001-11-22 | Geron Corporation | Ovine tissue for xenotransplantation |
| WO2001094636A2 (en) | 2000-06-05 | 2001-12-13 | Genetics Inst | Compositions, kits, and methods for identification and modulation of type i diabetes |
| CA2413857C (en) | 2000-06-28 | 2010-04-27 | Genetics Institute, Llc. | Pd-l2 molecules: pd-1 ligands and uses therefor |
| AU2001278204A1 (en) * | 2000-08-01 | 2002-02-13 | Xy Genetics, Llc | Methods of selecting and cloning animals |
| CA2422155A1 (en) | 2000-08-03 | 2002-02-14 | Wim Van Schooten | Production of humanized antibodies in transgenic animals |
| US6677500B2 (en) | 2000-08-15 | 2004-01-13 | Board Of Trustees Of The University Of Illinois | Ungulates expressing exogenous IGF-I in their milk |
| WO2002019811A2 (en) * | 2000-09-06 | 2002-03-14 | Nexia Biotechnologies, Inc. | Generation of transgenic animals using nuclear transfer and oocytes at the germinal vesicle stage |
| FR2814642B1 (fr) | 2000-10-03 | 2005-07-01 | Ass Pour Le Dev De La Rech En | Souris transgenique pour la recombinaison ciblee mediee par la cre-er modifiee |
| US20040029825A1 (en) * | 2001-10-03 | 2004-02-12 | Davies Christopher J | Methods of minimizing immunological rejection of a nuclear transfer fetus |
| US8105825B2 (en) * | 2000-10-03 | 2012-01-31 | Intrexon Corporation | Multiple inducible gene regulation system |
| JP2004526426A (ja) | 2000-11-28 | 2004-09-02 | ワイス | 前立腺癌の診断および治療に有用なｋｉａａ核酸およびポリペプチドの発現分析 |
| EP2316976A1 (en) | 2000-11-28 | 2011-05-04 | Wyeth LLC | Expression analysis of FKBP nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer |
| EP1356035B1 (en) | 2000-12-22 | 2011-03-16 | Kyowa Hakko Kirin Co., Ltd. | Methods for cloning non-human mammals using reprogrammed donor chromatin or donor cells |
| US7491534B2 (en) | 2000-12-22 | 2009-02-17 | Kirin Holdings Kabushiki Kaisha | Methods for altering cell fate to generate T-cells specific for an antigen of interest |
| US20020142397A1 (en) | 2000-12-22 | 2002-10-03 | Philippe Collas | Methods for altering cell fate |
| ATE466089T1 (de) | 2000-12-22 | 2010-05-15 | Agronomique Inst Nat Rech | Positionsunabhängige und gewebespezifische expression eines transgens in der milch eines transgen-tieres |
| EP1860199B1 (en) | 2001-01-12 | 2014-03-05 | Exelixis, Inc. | Modulating insulin receptor signaling |
| US20050177883A1 (en) | 2001-01-30 | 2005-08-11 | Rebholtz Paul C. | Systems of transferring embryos and managing recipients |
| WO2002062131A2 (en) * | 2001-02-02 | 2002-08-15 | Infigen, Inc. | Method of cloning transgenic mammalian animals using pseudonuclei |
| CA2438119C (en) * | 2001-02-20 | 2014-12-16 | Rheogene Holdings, Inc. | Chimeric retinoid x receptors and their use in a novel ecdysone receptor-based inducible gene expression system |
| US7309811B2 (en) | 2001-02-23 | 2007-12-18 | Elan Pharmaceuticals, Inc | Transgenic mice knockouts of BACE-1 |
| JP2002262716A (ja) * | 2001-03-07 | 2002-09-17 | National Agricultural Research Organization | 株化細胞を用いて家畜個体を作出する方法 |
| WO2002072762A2 (en) * | 2001-03-08 | 2002-09-19 | Advanced Cell Technology, Inc. | Use of rna interference for the creation of lineage specific es and other undifferentiated cells and production of differentiated cells in vitro by co-culture |
| AUPR363701A0 (en) | 2001-03-09 | 2001-04-05 | Garelag Pty Ltd | Method for the production of nuclear transfer embryos |
| US8981061B2 (en) | 2001-03-20 | 2015-03-17 | Novo Nordisk A/S | Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof |
| US7126039B2 (en) * | 2001-03-21 | 2006-10-24 | Geron Corporation | Animal tissue with carbohydrate antigens compatible for human transplantation |
| EP1370132A2 (en) * | 2001-03-21 | 2003-12-17 | Geron Corporation | Use of telomerase reverse transcriptase to create homozygous knockout animals |
| CA2442066C (en) | 2001-04-02 | 2005-11-01 | Wyeth | Pd-1, a receptor for b7-4, and uses therefor |
| US20030027330A1 (en) * | 2001-04-02 | 2003-02-06 | Robert Lanza | Method for facilitating the production of differentiated cell types and tissues from embryonic and adult pluripotent and multipotent cells |
| BR0208944A (pt) | 2001-04-16 | 2006-10-10 | Wyeth Corp | quadros de leitura aberta de streptococus pneumoniae codificando os antìgenos de polipeptìdeos e seus usos |
| US20030153044A1 (en) * | 2001-05-14 | 2003-08-14 | Monika Liljedahl | Tissues or organs for use in xenotransplantation |
| WO2002092791A1 (en) * | 2001-05-14 | 2002-11-21 | Stell | Tissues or organs for use in xenotransplantation |
| WO2003005810A2 (en) * | 2001-07-09 | 2003-01-23 | Alexion Pharmaceuticals Inc. | Cloned non-human mammals from contact inhibited donor cells |
| EP1900815B1 (en) | 2001-07-12 | 2016-09-07 | University of Massachusetts | In vivo production of small interfering RNAs that mediate gene silencing |
| ES2566561T3 (es) | 2001-07-12 | 2016-04-13 | University Of Massachusetts | Producción in vivo de ARN pequeños de interferencia que median el silenciamiento génico |
| US20030051264A1 (en) * | 2001-07-31 | 2003-03-13 | Monika Liljedahl | Genetically modified cows having reduced susceptibility to mad cow disease |
| US20030211603A1 (en) * | 2001-08-14 | 2003-11-13 | Earp David J. | Reprogramming cells for enhanced differentiation capacity using pluripotent stem cells |
| WO2003042362A2 (en) | 2001-11-09 | 2003-05-22 | Dana-Farber Cancer Institute, Inc. | PGC-1β, A NOVEL PGC-1 HOMOLOGUE AND USES THEREFOR |
| US20050170506A1 (en) * | 2002-01-16 | 2005-08-04 | Primegen Biotech Llc | Therapeutic reprogramming, hybrid stem cells and maturation |
| US20030134422A1 (en) * | 2002-01-16 | 2003-07-17 | Sayre Chauncey Bigelow | Stem cell maturation for all tissue lines |
| US20050090004A1 (en) * | 2003-01-16 | 2005-04-28 | Sayre Chauncey B. | Stem cell maturation for all tissue lines |
| CN100575485C (zh) | 2002-01-23 | 2009-12-30 | 犹他大学研究基金会 | 使用锌指核酸酶的定向染色体诱变 |
| KR100502695B1 (ko) * | 2002-02-28 | 2005-07-25 | 한국생명공학연구원 | 형질전환 효율이 향상된 복제수정란의 대량 생산 방법 |
| WO2003080809A2 (en) | 2002-03-21 | 2003-10-02 | Sangamo Biosciences, Inc. | Methods and compositions for using zinc finger endonucleases to enhance homologous recombination |
| GB0207299D0 (en) * | 2002-03-28 | 2002-05-08 | Franks Christopher R | Stem cell therapy |
| NZ535367A (en) * | 2002-04-01 | 2008-01-31 | Gtc Biotherapeutics Inc | A method for selecting cell lines to be used for nuclear transfer in mammalian species |
| US20030207448A1 (en) * | 2002-05-06 | 2003-11-06 | Revera Gregory Henry | Methodologies for the creation of pluripotent or multipotent human stem cells without creating or destroying a human embryo |
| GB0211904D0 (en) * | 2002-05-23 | 2002-07-03 | Medical Res Council | Nuclear transfer |
| AU2003247514A1 (en) * | 2002-06-11 | 2003-12-22 | Roy Ogle | Meningeal-derived stem cells |
| US7612250B2 (en) | 2002-07-29 | 2009-11-03 | Trustees Of Tufts College | Nuclear transfer embryo formation method |
| EP2314716A1 (en) | 2002-08-20 | 2011-04-27 | Millennium Pharmaceuticals, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer |
| CA2497913C (en) | 2002-09-05 | 2014-06-03 | California Institute Of Technology | Use of chimeric nucleases to stimulate gene targeting |
| WO2004032877A2 (en) | 2002-10-10 | 2004-04-22 | Wyeth | Compositions, organisms and methodologies employing a novel human kinase |
| US20040077077A1 (en) * | 2002-10-18 | 2004-04-22 | Xiangzhong Yang | Novel methods for the production of cloned mammals, mammals cloned according to the methods, and methods of use of same |
| AU2003284887A1 (en) | 2002-10-24 | 2004-05-13 | Wyeth | Calcineurin-like human phosphoesterase |
| RU2384059C2 (ru) | 2002-11-08 | 2010-03-20 | Киова Хакко Кирин Ко., Лтд. | Трансгенные копытные животные, имеющие пониженную активность прионного белка, и их применения |
| BR0316111A (pt) | 2002-11-21 | 2005-09-13 | Wyeth Corp | Métodos para diagnosticar rcc e outros tumores sólidos |
| WO2004050831A2 (en) | 2002-11-27 | 2004-06-17 | Wyeth | Compositions, organisms and methodologies employing a novel human kinase |
| CA2509465A1 (en) * | 2002-12-10 | 2004-06-24 | Gtc Biotherapeutics, Inc. | Method and system for utilizing somatic cell nuclear transfer embryos as cell donors for additional nuclear transfer |
| US7482117B2 (en) | 2002-12-20 | 2009-01-27 | Celera Corporation | Genetic polymorphisms associated with myocardial infarction, methods of detection and uses thereof |
| AU2004203749A1 (en) | 2003-01-06 | 2004-07-22 | Wyeth | Compositions and methods for diagnosing and treating colon cancers |
| FR2855183B1 (fr) | 2003-05-23 | 2005-08-12 | Agronomique Inst Nat Rech | Procede de clonage du rat par transfert nucleaire |
| PL1633767T3 (pl) | 2003-06-02 | 2019-07-31 | University Of Massachusetts | Sposoby i kompozycje do kontrolowania wydajności wyciszania rna |
| ES2357116T5 (es) | 2003-06-02 | 2021-09-03 | Univ Massachusetts | Métodos y composiciones para mejorar la eficacia y especificad de FNAi |
| US11311574B2 (en) | 2003-08-08 | 2022-04-26 | Sangamo Therapeutics, Inc. | Methods and compositions for targeted cleavage and recombination |
| US8409861B2 (en) * | 2003-08-08 | 2013-04-02 | Sangamo Biosciences, Inc. | Targeted deletion of cellular DNA sequences |
| US20120196370A1 (en) | 2010-12-03 | 2012-08-02 | Fyodor Urnov | Methods and compositions for targeted genomic deletion |
| US7888121B2 (en) * | 2003-08-08 | 2011-02-15 | Sangamo Biosciences, Inc. | Methods and compositions for targeted cleavage and recombination |
| JP2007502119A (ja) | 2003-08-14 | 2007-02-08 | エクセリクシス， インク． | βカテニン経路のモディファイヤーとしてのＵＰｓ及び使用方法 |
| CN102517381A (zh) | 2003-10-07 | 2012-06-27 | 千年药品公司 | 用于鉴定、评价、预防和治疗卵巢癌的核酸分子和蛋白质 |
| WO2005046450A2 (en) | 2003-11-12 | 2005-05-26 | Children's Hospital Medical Center | Method for diagnosis and treatment of pulmonary disorders |
| EP2386657B1 (en) | 2003-11-26 | 2014-01-08 | Celera Corporation | Genetic polymorphisms associated with cardiovascular disorders and drug response, methods of detection and uses thereof |
| US7972854B2 (en) | 2004-02-05 | 2011-07-05 | Sangamo Biosciences, Inc. | Methods and compositions for targeted cleavage and recombination |
| AU2005237494B2 (en) | 2004-04-22 | 2010-06-10 | Kyowa Hakko Kirin Co., Ltd | Transgenic animals and uses thereof |
| JP5236286B2 (ja) | 2004-05-07 | 2013-07-17 | セレラ コーポレーション | 肝線維症に関連する遺伝的多型、その検出方法および使用 |
| JP2006081542A (ja) * | 2004-08-18 | 2006-03-30 | Institute Of Physical & Chemical Research | クローン哺乳動物の作成方法 |
| JP2008517931A (ja) | 2004-10-22 | 2008-05-29 | ダナ−ファーバー キャンサー インスティチュート，インコーポレイテッド | 脂質関連疾患および障害を処置するための、ＰＧＣ−１βを調節するための方法および組成物 |
| GB0426146D0 (en) | 2004-11-29 | 2004-12-29 | Bioxell Spa | Therapeutic peptides and method |
| CN1274829C (zh) | 2004-12-10 | 2006-09-13 | 四川大学华西医院 | 抗eb病毒所致肿瘤多肽及其应用与制备方法 |
| JP5590697B2 (ja) | 2005-03-11 | 2014-09-17 | セレラ コーポレーション | 冠動脈心疾患に関連する遺伝的多型、その検出方法および使用 |
| US20060286666A1 (en) * | 2005-06-17 | 2006-12-21 | Kang Ji Y | Methods and apparatuses for culturing stem cell using biomaterial shell |
| US20070056050A1 (en) * | 2005-06-29 | 2007-03-08 | Clokie Cameron M L | PRODUCTION OF BONE MORPHOGENIC PROTEINS (BMPs) IN TRANSGENIC MAMMALS |
| KR100733012B1 (ko) | 2005-07-26 | 2007-06-28 | 재단법인서울대학교산학협력재단 | 복제된 개과 동물 및 이의 생산 방법 |
| NZ565711A (en) | 2005-08-09 | 2011-10-28 | Revivicor Inc | Transgenic ungulates expressing a porcine CTLA4 peptide fused to an immunoglobulin |
| US20100040636A1 (en) | 2005-09-09 | 2010-02-18 | The Johns Hopkins University | Manipulation of Regulatory T Cell and Dc Function By Targeting Neuritin Gene Using Antibodies, Agonists and Antagonists |
| WO2007035778A2 (en) | 2005-09-19 | 2007-03-29 | Histogenics Corporation | Cell-support matrix and a method for preparation thereof |
| US7799530B2 (en) | 2005-09-23 | 2010-09-21 | Celera Corporation | Genetic polymorphisms associated with cardiovascular disorders and drug response, methods of detection and uses thereof |
| US7695911B2 (en) | 2005-10-26 | 2010-04-13 | Celera Corporation | Genetic polymorphisms associated with Alzheimer's Disease, methods of detection and uses thereof |
| WO2007124019A2 (en) | 2006-04-21 | 2007-11-01 | Gtc Biotherapeutics, Inc. | Methods and products related to the transfer of molecules from blood to the mammary gland |
| ATE536374T1 (de) | 2006-09-01 | 2011-12-15 | Therapeutic Human Polyclonals Inc | Erhöhte expression von humanem oder humanisiertem immunglobulin bei nicht-humanen transgenen tieren |
| EP2639319B1 (en) | 2006-09-11 | 2015-07-08 | Celera Corporation | Genetic polymorphisms associated with Psoriasis, methods of detection and uses thereof |
| EP2431483B1 (en) | 2006-10-20 | 2015-04-01 | Celera Corporation | Genetic polymorphisms associated with venous thrombosis, methods of detection and uses thereof |
| WO2008085891A1 (en) * | 2007-01-05 | 2008-07-17 | Worcester Polytechnic Institute | Oocyte spindle-associated factors improve somatic cell cloning |
| KR100829426B1 (ko) | 2007-01-17 | 2008-05-15 | 재단법인서울대학교산학협력재단 | 복제개의 생산 방법 |
| US20080222745A1 (en) * | 2007-03-07 | 2008-09-11 | Utah State University | Colcemid-Treatment of Oocytes to enhance Nuclear Transfer Cloning |
| KR100868245B1 (ko) | 2007-05-29 | 2008-11-11 | 강원대학교산학협력단 | 데메콜친 처리에 의한 효율적인 복제 동물의 생산방법 |
| US8663980B2 (en) | 2007-10-26 | 2014-03-04 | Janssen Biotech, Inc. | Vectors, host cells, and methods of production and uses |
| US8039212B2 (en) | 2007-11-05 | 2011-10-18 | Celera Corporation | Genetic polymorphisms associated with liver fibrosis, methods of detection and uses thereof |
| KR101105248B1 (ko) | 2008-01-04 | 2012-01-17 | 재단법인서울대학교산학협력재단 | 형질전환된 복제개의 생산방법 |
| US20090221620A1 (en) | 2008-02-20 | 2009-09-03 | Celera Corporation | Gentic polymorphisms associated with stroke, methods of detection and uses thereof |
| WO2009114185A2 (en) | 2008-03-12 | 2009-09-17 | The Rockefeller University | Methods and compositions for translational profiling and molecular phenotyping |
| US8288094B2 (en) | 2008-04-09 | 2012-10-16 | Institut Pasteur | APOBEC3 mediated DNA editing |
| WO2009134130A2 (en) | 2008-05-02 | 2009-11-05 | Pharming Intellectual Property Bv | Treatment of bleeding with low half-life fibrinogen |
| EP2295538B1 (en) * | 2008-07-07 | 2015-10-21 | Takara Bio Inc. | Method for production of pluripotent stem cell |
| US8216786B2 (en) | 2008-07-09 | 2012-07-10 | Celera Corporation | Genetic polymorphisms associated with cardiovascular diseases, methods of detection and uses thereof |
| US9181315B2 (en) | 2009-01-08 | 2015-11-10 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for induced brown fat differentiation |
| US8722964B2 (en) | 2009-04-23 | 2014-05-13 | Transposagen Biopharmaceuticals, Inc. | Genetically engineered or transgenic rats exhibiting a cancer phenotype due to a disruption of germline tumor suppressor genes |
| EP2267153A1 (en) | 2009-05-26 | 2010-12-29 | Université Claude Bernard Lyon 1 | Identification of netrin-1 receptor unc5c gene mutation in solid cancers |
| US9314005B2 (en) | 2009-07-01 | 2016-04-19 | Transposagen Biopharmaceuticals, Inc. | Genetically modified rat models for severe combined immunodeficiency (SCID) |
| EP2456876A2 (en) | 2009-07-24 | 2012-05-30 | Transposagen Biopharmaceuticals, Inc. | Genetically modified rat models for cytokine-cytokine signaling pathways |
| WO2011014721A2 (en) | 2009-07-30 | 2011-02-03 | Transposagen Biopharmaceuticals, Inc. | Genetically modified rat models for pharmacokinetics |
| EP2461672A2 (en) | 2009-08-05 | 2012-06-13 | Transposagen Biopharmaceuticals, Inc. | Genetically modified rat models for drug metabolism |
| US20120151609A1 (en) | 2009-08-20 | 2012-06-14 | Ostertag Eric M | Genetically Modified Rat Models for Pain |
| US9420770B2 (en) | 2009-12-01 | 2016-08-23 | Indiana University Research & Technology Corporation | Methods of modulating thrombocytopenia and modified transgenic pigs |
| JP2013520162A (ja) | 2010-01-22 | 2013-06-06 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | 代謝障害の同定、査定、予防および治療のための組成物、キットおよび方法 |
| TWI518325B (zh) | 2010-02-04 | 2016-01-21 | 自治醫科大學 | 對ａｌｋ抑制劑具有先抗性或後抗性癌症的識別、判斷和治療 |
| CN107098958B (zh) | 2010-03-26 | 2021-11-05 | 达特茅斯大学理事会 | Vista调节性t细胞介体蛋白、vista结合剂及其用途 |
| US10745467B2 (en) | 2010-03-26 | 2020-08-18 | The Trustees Of Dartmouth College | VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders |
| US20150231215A1 (en) | 2012-06-22 | 2015-08-20 | Randolph J. Noelle | VISTA Antagonist and Methods of Use |
| US8383793B2 (en) | 2010-04-15 | 2013-02-26 | St. Jude Children's Research Hospital | Methods and compositions for the diagnosis and treatment of cancer resistant to anaplastic lymphoma kinase (ALK) kinase inhibitors |
| US20110269735A1 (en) | 2010-04-19 | 2011-11-03 | Celera Corporation | Genetic polymorphisms associated with statin response and cardiovascular diseases, methods of detection and uses thereof |
| WO2012020077A1 (en) | 2010-08-11 | 2012-02-16 | Inserm (Institut Mational De La Santé Et De La Recherche Médicale) | Methods of growing an embryo to a blastocyst stage of development |
| US20120108651A1 (en) | 2010-11-02 | 2012-05-03 | Leiden University Medical Center (LUMC) Acting on Behalf of Academic Hospital Leiden (AZL) | Genetic polymorphisms associated with venous thrombosis and statin response, methods of detection and uses thereof |
| US8748178B2 (en) | 2010-11-23 | 2014-06-10 | The New York Stem Cell Foundation | Method for producing pluripotent stem cells |
| CN104774871A (zh) | 2011-02-14 | 2015-07-15 | 雷维维科公司 | 用于血管化异种移植物及其衍生物的异种移植的遗传修饰的猪 |
| WO2012129198A1 (en) | 2011-03-23 | 2012-09-27 | Transposagen Biopharmaceuticals, Inc. | Genetically modified rat models for obesity and diabetes |
| KR102574897B1 (ko) | 2011-05-16 | 2023-09-06 | 더 큐레이터스 오브 더 유니버시티 오브 미주리 | 돼지 생식기 호흡기 증후군 바이러스 내성 동물 |
| US8969519B2 (en) | 2011-09-13 | 2015-03-03 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for brown fat induction and activity using FNDC5 |
| CN102391989A (zh) * | 2011-10-12 | 2012-03-28 | 扬州大学 | 转基因动物重组产物精确分析检验方法 |
| HRP20181817T1 (hr) | 2012-02-15 | 2018-12-28 | Novo Nordisk A/S | Anitijela koja vezuju protein 1 prepoznavanja peptidoglikana |
| US9550830B2 (en) | 2012-02-15 | 2017-01-24 | Novo Nordisk A/S | Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1) |
| CN104220456B (zh) | 2012-02-15 | 2018-02-23 | 诺和诺德股份有限公司 | 结合并阻断髓样细胞表达的触发受体‑1 (trem‑1)的抗体 |
| FI3421486T3 (fi) | 2012-06-22 | 2023-12-15 | Dartmouth College | Uusia vista-ig-rakenteita ja vista-ig:n käyttö autoimmuuni-, allergia- ja tulehdushäiriöiden hoitamiseksi |
| US9890215B2 (en) | 2012-06-22 | 2018-02-13 | King's College London | Vista modulators for diagnosis and treatment of cancer |
| JP6368308B2 (ja) | 2012-09-07 | 2018-08-01 | トラスティーズ・オブ・ダートマス・カレッジ | 癌の診断および治療のためのｖｉｓｔａ調節剤 |
| US20140115728A1 (en) | 2012-10-24 | 2014-04-24 | A. Joseph Tector | Double knockout (gt/cmah-ko) pigs, organs and tissues |
| BR112015019348A2 (pt) | 2013-02-13 | 2017-08-22 | Lab Francais Du Fractionnement | Métodos para produção de proteína com glicosilação modificada e com sialilação aumentada, para aumentar a atividade de sialil transferase na glândula mamária e para produzir sialil transferase, proteína com glicosilação modificada ou proteína com sialilação aumentada, composição, sialil transferase, mamífero transgênico, e, célula epitelial mamária |
| EP3594230A1 (en) | 2013-02-13 | 2020-01-15 | Laboratoire Français du Fractionnement et des Biotechnologies | Highly galactosylated anti-tnf-alpha antibodies and uses thereof |
| US20160102319A1 (en) | 2013-04-30 | 2016-04-14 | Konkuk University Industrial Cooperation Corp. | Cmp-acetylneuraminic acid hydroxylase targeting vector, transgenic animal for xenotransplantation introduced with the vector, and method of manufacturing the same |
| SG10201912797XA (en) | 2013-12-24 | 2020-02-27 | Janssen Pharmaceutica Nv | Anti-vista antibodies and fragments |
| US11014987B2 (en) | 2013-12-24 | 2021-05-25 | Janssen Pharmaceutics Nv | Anti-vista antibodies and fragments, uses thereof, and methods of identifying same |
| CA2935804A1 (en) | 2014-01-14 | 2015-07-23 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for identification, assessment, prevention, and treatment of melanoma using pd-l1 isoforms |
| CN107073109B (zh) | 2014-06-11 | 2021-08-06 | 凯西·A·格林 | Vista激动剂和拮抗剂抑制或增强体液免疫的用途 |
| ES2974575T3 (es) | 2014-07-17 | 2024-06-27 | Novo Nordisk As | Mutagénesis dirigida al sitio de anticuerpos contra TREM-1 para disminuir la viscosidad |
| US10077420B2 (en) | 2014-12-02 | 2018-09-18 | Histogenics Corporation | Cell and tissue culture container |
| CA2969730A1 (en) | 2014-12-05 | 2016-06-09 | Immunext, Inc. | Identification of vsig8 as the putative vista receptor and its use thereof to produce vista/vsig8 modulators |
| WO2016094481A1 (en) | 2014-12-09 | 2016-06-16 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a humanized cluster of differentiation 274 gene |
| CN104823921A (zh) * | 2015-05-21 | 2015-08-12 | 蒙汉勤 | 一种用于人体烧伤皮肤移植及医学实验的小型香猪的饲养技术 |
| MX388164B (es) | 2015-06-24 | 2025-03-19 | Janssen Pharmaceutica Nv | Anticuerpos y fragmentos anti-vista |
| FR3038517B1 (fr) | 2015-07-06 | 2020-02-28 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Utilisation de fragments fc modifies en immunotherapie |
| EP3331355B1 (en) | 2015-08-06 | 2024-04-03 | The Curators of the University of Missouri | Porcine reproductive and respiratory syndrome virus (prrsv)-resistant porcine and cells having modified cd163 genes |
| WO2017075329A2 (en) | 2015-10-29 | 2017-05-04 | Dana-Farber Cancer Institute, Inc. | Methods for identification, assessment, prevention, and treatment of metabolic disorders using pm20d1 and n-lipidated amino acids |
| US10899836B2 (en) | 2016-02-12 | 2021-01-26 | Janssen Pharmaceutica Nv | Method of identifying anti-VISTA antibodies |
| NZ746658A (en) | 2016-04-15 | 2025-09-26 | Immunext Inc | Anti-human vista antibodies and use thereof |
| WO2019018635A1 (en) | 2017-07-19 | 2019-01-24 | Children's Medical Center Corporation | COMPOSITIONS AND METHODS FOR TREATING DISEASES ASSOCIATED WITH IMPRESSIVE FAULT |
| AU2019248547B2 (en) | 2018-04-02 | 2025-07-17 | Bristol-Myers Squibb Company | Anti-TREM-1 antibodies and uses thereof |
| AU2019247490A1 (en) | 2018-04-06 | 2020-10-22 | Children's Medical Center Corporation | Compositions and methods for somatic cell reprogramming and modulating imprinting |
| US11160260B2 (en) | 2018-04-17 | 2021-11-02 | The Curators Of The University Of Missouri | Methods for protecting porcine fetuses from infection with porcine reproductive and respiratory syndrome virus (PRRSV) |
| WO2020041360A1 (en) | 2018-08-21 | 2020-02-27 | Quidel Corporation | Dbpa antibodies and uses thereof |
| EP4077376A2 (en) | 2019-12-19 | 2022-10-26 | Quidel Corporation | Monoclonal antibody fusions |
| WO2022109316A1 (en) | 2020-11-20 | 2022-05-27 | Revivicor, Inc. | Multi-transgenic pigs with growth hormone receptor knockout for xenotransplantation |
| WO2023044100A1 (en) | 2021-09-20 | 2023-03-23 | Revivicor, Inc. | Multitran scenic pigs comprising ten genetic modifications for xenotransplantation |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR890003947B1 (ko) * | 1985-12-11 | 1989-10-13 | 가부시기가이샤 시마즈세이사구쇼 | 세포융합장치 |
| US5057420A (en) * | 1987-06-05 | 1991-10-15 | Granada Biosciences, Inc. | Bovine nuclear transplantation |
| GB8714426D0 (en) * | 1987-06-19 | 1987-07-22 | Agricultural & Food Res | Culture technique |
| CA2059199A1 (en) * | 1992-01-10 | 1993-07-11 | Steen Willadsen | Method for producing mature reconstituted mammalian eggs by nuclear transplantation |
| GB2265909B (en) * | 1992-04-01 | 1996-03-20 | Inst Of Animal Physiology And | Fusion of donor nucleus with recipient cytoplast in the absence of calcium ion |
| DE69332758D1 (de) * | 1992-09-22 | 2003-04-17 | Us Gov Health & Human Serv | Taxol zur behandlung von lymphomen und brustkrebs und zur verminderung der multi-drug resistenz gegen taxol |
| CA2092258A1 (en) * | 1992-12-30 | 1994-07-01 | Steven L. Stice | Synchronized donor cells for bovine nuclear transfer |
| US5496720A (en) * | 1993-02-10 | 1996-03-05 | Susko-Parrish; Joan L. | Parthenogenic oocyte activation |
| US5523226A (en) * | 1993-05-14 | 1996-06-04 | Biotechnology Research And Development Corp. | Transgenic swine compositions and methods |
| EP1649853A3 (en) * | 1993-07-29 | 2006-11-22 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Microtubule stabilizing agents for treating atherosclerosis or restenosis |
| AU1439295A (en) * | 1993-12-17 | 1995-07-03 | Abs Global, Inc. | Ungulate preblastocyst derived embryonic stem cells and use thereof to produce cloned transgenic and chimeric ungulates |
| WO1995017500A1 (en) * | 1993-12-23 | 1995-06-29 | Abs Global, Inc. | Embryonic stem cells as nuclear donors and nuclear transfer techniques to produce chimeric and transgenic animals |
| GB9417831D0 (en) * | 1994-09-05 | 1994-10-26 | Biotech & Biolog Scien Res | Biological manipulation |
| GB9517780D0 (en) * | 1995-08-31 | 1995-11-01 | Roslin Inst Edinburgh | Biological manipulation |
| US7307198B2 (en) | 1995-08-31 | 2007-12-11 | Roslin Institute | Ungulates produced by nuclear transfer of G1 cells |
| GB9517779D0 (en) | 1995-08-31 | 1995-11-01 | Roslin Inst Edinburgh | Biological manipulation |
| US6235969B1 (en) * | 1997-01-10 | 2001-05-22 | University Of Massachusetts | Cloning pigs using donor nuclei from non-quiescent differentiated cells |
| US6215041B1 (en) * | 1997-01-10 | 2001-04-10 | University Of Mmassachusetts | Cloning using donor nuclei from a non-quiesecent somatic cells |
| US5945577A (en) * | 1997-01-10 | 1999-08-31 | University Of Massachusetts As Represented By Its Amherst Campus | Cloning using donor nuclei from proliferating somatic cells |
| US6011197A (en) * | 1997-03-06 | 2000-01-04 | Infigen, Inc. | Method of cloning bovines using reprogrammed non-embryonic bovine cells |
| AU8587598A (en) * | 1997-07-26 | 1999-02-16 | Wisconsin Alumni Research Foundation | Trans-species nuclear transfer |
| US6225243B1 (en) * | 1998-08-03 | 2001-05-01 | Bba Nonwovens Simpsonville, Inc. | Elastic nonwoven fabric prepared from bi-component filaments |
| GB2365445A (en) * | 1998-10-12 | 2002-02-20 | Geron Bio Med Ltd | Porcine occcytes with improved developmental competence |
| US20050156424A1 (en) * | 2000-02-29 | 2005-07-21 | Thyssenkrupp Presta Ag | Steering column and manufacturing method thereof |
-
1995
- 1995-08-31 GB GBGB9517780.4A patent/GB9517780D0/en active Pending
-
1996
- 1996-08-30 JP JP50999697A patent/JP4081613B2/ja not_active Expired - Fee Related
- 1996-08-30 HU HU9900234A patent/HUP9900234A3/hu unknown
- 1996-08-30 EP EP96928587A patent/EP0849990B1/en not_active Expired - Lifetime
- 1996-08-30 AT AT96928587T patent/ATE199115T1/de active
- 1996-08-30 BR BRPI9610034-6A patent/BR9610034B1/pt not_active IP Right Cessation
- 1996-08-30 WO PCT/GB1996/002099 patent/WO1997007669A1/en not_active Ceased
- 1996-08-30 AU AU68310/96A patent/AU716956C/en not_active Expired
- 1996-08-30 PL PL96325331A patent/PL325331A1/xx unknown
- 1996-08-30 CA CA2229568A patent/CA2229568C/en not_active Expired - Lifetime
- 1996-08-30 NZ NZ316149A patent/NZ316149A/en not_active IP Right Cessation
- 1996-08-30 CN CNA2005101163312A patent/CN1769431A/zh active Pending
- 1996-08-30 ZA ZA9607390A patent/ZA967390B/xx unknown
- 1996-08-30 DE DE69611793T patent/DE69611793T2/de not_active Expired - Lifetime
- 1996-08-30 GB GB9802915A patent/GB2318578B/en not_active Expired - Lifetime
- 1996-08-30 EP EP98203752A patent/EP0930009A1/en not_active Withdrawn
- 1996-08-30 KR KR1019980701381A patent/KR100533476B1/ko not_active Expired - Lifetime
- 1996-08-30 CN CNB2005101163327A patent/CN100422317C/zh not_active Expired - Lifetime
- 1996-08-30 KR KR1020067006297A patent/KR20060053008A/ko not_active Ceased
- 1996-08-30 SI SI9630282T patent/SI0849990T1/xx unknown
- 1996-08-30 NZ NZ337311A patent/NZ337311A/en not_active IP Right Cessation
- 1996-08-30 CZ CZ98608A patent/CZ60898A3/cs unknown
- 1996-08-30 SG SG1999000937A patent/SG75155A1/en unknown
- 1996-08-30 CN CNB961978910A patent/CN1230533C/zh not_active Expired - Lifetime
- 1996-08-30 EP EP99204105A patent/EP1005789A3/en not_active Withdrawn
- 1996-08-30 KR KR1020077007530A patent/KR20070047848A/ko not_active Withdrawn
- 1996-08-30 IL IL12329896A patent/IL123298A0/xx unknown
- 1996-08-30 DK DK96928587T patent/DK0849990T3/da active
- 1996-08-30 KR KR1020057014692A patent/KR100793220B1/ko not_active Expired - Lifetime
- 1996-08-30 ES ES96928587T patent/ES2155197T3/es not_active Expired - Lifetime
-
1997
- 1997-02-19 US US08/802,282 patent/US6147276A/en not_active Expired - Lifetime
-
1998
- 1998-02-27 NO NO980845A patent/NO980845L/no unknown
-
1999
- 1999-02-19 NZ NZ334288A patent/NZ334288A/en not_active IP Right Cessation
-
2004
- 2004-08-11 US US10/915,338 patent/US7232938B2/en not_active Expired - Fee Related
-
2005
- 2005-11-03 US US11/265,113 patent/US7514258B2/en not_active Expired - Fee Related
- 2005-11-30 JP JP2005345712A patent/JP2006217913A/ja active Pending
-
2006
- 2006-10-06 US US11/543,786 patent/US20070033664A1/en not_active Abandoned
- 2006-10-06 US US11/544,039 patent/US7355094B2/en not_active Expired - Fee Related
Non-Patent Citations (1)
| Title |
|---|
| Biol. Reprod., Vol.49(5), pp.933-942 (1993.11.) * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101398220B1 (ko) | 2006-10-30 | 2014-05-22 | 건국대학교 산학협력단 | 형질전환 배아 생성방법 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100533476B1 (ko) | 핵이식용의 휴지기 세포 모집단 | |
| KR100533477B1 (ko) | 핵이식용 세포질 수용체로서의 불활성화 난모세포 | |
| GB2331751A (en) | Quiescent cell populations for nuclear transfer | |
| AU2003271356B9 (en) | Quiescent cell population for nuclear transfer | |
| Dinnyés et al. | Cloning of rabbits | |
| MXPA98001646A (en) | Cellular populations inactive for transfer celu | |
| WO1999063061A1 (en) | Es cell lines from somatic cells via embryo reconstruction and selective ablation | |
| HK1090089B (en) | Quiescent cell populations for nuclear transfer | |
| AU2005246962A1 (en) | Quiescent cell population for nuclear transfer | |
| MXPA98001645A (en) | Oocytes inactivated as receptors of cytopllasto for nuclear transfer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 19980225 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| N231 | Notification of change of applicant | ||
| PN2301 | Change of applicant |
Patent event date: 19980903 Comment text: Notification of Change of Applicant Patent event code: PN23011R01D |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| AMND | Amendment | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20010828 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20031128 Patent event code: PE09021S01D |
|
| AMND | Amendment | ||
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20040727 Patent event code: PE09021S01D |
|
| AMND | Amendment | ||
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20050408 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20040727 Comment text: Notification of reason for refusal Patent event code: PE06011S01I Patent event date: 20031128 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |
|
| J201 | Request for trial against refusal decision | ||
| PJ0201 | Trial against decision of rejection |
Patent event date: 20050711 Comment text: Request for Trial against Decision on Refusal Patent event code: PJ02012R01D Patent event date: 20050408 Comment text: Decision to Refuse Application Patent event code: PJ02011S01I Appeal kind category: Appeal against decision to decline refusal Decision date: 20050921 Appeal identifier: 2005101004457 Request date: 20050711 |
|
| A107 | Divisional application of patent | ||
| AMND | Amendment | ||
| PA0104 | Divisional application for international application |
Comment text: Divisional Application for International Patent Patent event code: PA01041R01D Patent event date: 20050810 |
|
| PB0901 | Examination by re-examination before a trial |
Comment text: Amendment to Specification, etc. Patent event date: 20050810 Patent event code: PB09011R02I Comment text: Request for Trial against Decision on Refusal Patent event date: 20050711 Patent event code: PB09011R01I Comment text: Amendment to Specification, etc. Patent event date: 20041126 Patent event code: PB09011R02I Comment text: Amendment to Specification, etc. Patent event date: 20040227 Patent event code: PB09011R02I Comment text: Amendment to Specification, etc. Patent event date: 20010828 Patent event code: PB09011R02I |
|
| B701 | Decision to grant | ||
| PB0701 | Decision of registration after re-examination before a trial |
Patent event date: 20050921 Comment text: Decision to Grant Registration Patent event code: PB07012S01D Patent event date: 20050830 Comment text: Transfer of Trial File for Re-examination before a Trial Patent event code: PB07011S01I |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20051129 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20051130 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration | ||
| PR1001 | Payment of annual fee |
Payment date: 20081126 Start annual number: 4 End annual number: 4 |
|
| J204 | Request for invalidation trial [patent] | ||
| PJ0204 | Invalidation trial for patent |
Patent event date: 20090811 Comment text: Request for Trial Patent event code: PJ02042R01D Patent event date: 20051129 Comment text: Registration of Establishment Patent event code: PJ02041E01I Appeal kind category: Invalidation Request date: 20090811 Decision date: 20091117 Appeal identifier: 2009100001926 |
|
| J121 | Written withdrawal of request for trial | ||
| PJ1201 | Withdrawal of trial |
Patent event code: PJ12011R01D Patent event date: 20091117 Comment text: Written Withdrawal of Request for Trial Appeal identifier: 2009100001926 Request date: 20090811 Appeal kind category: Invalidation Decision date: 20091117 |
|
| PR1001 | Payment of annual fee |
Payment date: 20091123 Start annual number: 5 End annual number: 5 |
|
| PR1001 | Payment of annual fee |
Payment date: 20101126 Start annual number: 6 End annual number: 6 |
|
| PR1001 | Payment of annual fee |
Payment date: 20111102 Start annual number: 7 End annual number: 7 |
|
| FPAY | Annual fee payment |
Payment date: 20121031 Year of fee payment: 8 |
|
| PR1001 | Payment of annual fee |
Payment date: 20121031 Start annual number: 8 End annual number: 8 |
|
| FPAY | Annual fee payment |
Payment date: 20131101 Year of fee payment: 9 |
|
| PR1001 | Payment of annual fee |
Payment date: 20131101 Start annual number: 9 End annual number: 9 |
|
| FPAY | Annual fee payment |
Payment date: 20141107 Year of fee payment: 10 |
|
| PR1001 | Payment of annual fee |
Payment date: 20141107 Start annual number: 10 End annual number: 10 |
|
| FPAY | Annual fee payment |
Payment date: 20151030 Year of fee payment: 11 |
|
| PR1001 | Payment of annual fee |
Payment date: 20151030 Start annual number: 11 End annual number: 11 |
|
| PC1801 | Expiration of term |